Biologics Outsourcing Market by Product (Antibody, Recombinant Protein, Vaccines, and Others), by Type (Kits & Reagents and Instruments), by Sources (Microbial, Mammalian and Others) and for Applications (Vaccine & Therapeutics Development, Blood & Blood Related Products Testing, Cellular and Gene Therapy, Tissue and Tissue Related Products Testing, and Stem Cell Research): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Global biologics outsourcing market is expected to reach approximately USD 32,000.0 million by 2024 and is expected to exhibit a CAGR of more than 18.0% between 2017 and 2024.

Choose License

05-Feb-2018 | Number of pages: 130 | Report Code: ZMR-2577 | Report Format : | Status : Published

Abstract

Report Brief

  • The report covers forecast and analysis for the biologics outsourcing market on a global and regional level
  • The report includes the positive and the negative factors that are influencing the growth of the market
  • Detailed information about the market opportunities are discussed
  • The key target audience for the market has been determined in the report
  • The revenue generated by the prominent industry players has been analyzed in the report
  • The market numbers have been calculated using top-down and the bottom-up approaches 
  • The biologics outsourcing market has been analyzed using Porter’s Five Forces Analysis
  • The market is segmented on the basis of product, sources, type, and applications, which in turn bifurcated on regional level as well
  • All the segments have been evaluated based on the present and the future trends
  • The report deals with the in-depth quantitative and qualitative analyses of the Biologics Outsourcing market
  • The report includes the detailed company profiles of the prominent market players

Market Summary

Overview

In global biologics outsourcing market, the biologics are expected to be a significant area of growth, however, they are starting from a lower base and there is a greater bias against outsourcing biologics production. Outsourcing is increasing as a percentage of the whole manufacturing capacity due to relatively more of new product manufacturing is outsourced and facilities with products that become generic are non-core and are being divested. Increasing investments in the research & development of biologics are significantly propelling the outsourcing market among the big as well as small pharmaceutical and biotechnological industries.

Value

The global biologics outsourcing market was valued at around USD 8,420.0 million in the year 2016 and it is expected to reach approximately USD 32,000.0 million by 2024. The global biologics outsourcing market is expected to grow at a CAGR of over 18.0% between 2017 and 2024.

Drivers and Restraints

The major factor driving the growth of biologics outsourcing market is the increasing investments in research & development of biologic drugs. Because of the facilities with products that become generic are non-core and are being divested and relatively more of new product manufacturing is outsourced the outsourcing is increasing as a percentage of the whole manufacturing capacity. Using a third-party manufacturer can act as an additional site in a multiple site supply strategy, provide backup capacity and increased supply security. In addition, biologics capacity has been built up by CMOs to enable more production to be externalized which will ultimately propel the biologics outsourcing market.

Development of Biologics required high capital and time investment which is expected to arrest the growth of this industry in the years to come.

Global Biologics Outsourcing Market

Segmentation

Antibody product segment is accounted for the largest market share in 2017 and expected to dominate the market by the end of forecast period. The antibody segment is further sub-segmented into a monoclonal antibody, bi-specific antibody, and antibody drug conjugates. From which monoclonal antibodies accounted for the largest market share. Increasing approval for an orphan indication has climbed to more than 50% in the current decade will propel the segment during the forecast period.

Microbial source segment dominates the mammalian and other sources such as Transgenic Models, Avian, and etc. number of products discovered and manufactured by microbial sources will keep the segment dominance throughout the forecast period.
The kits & reagents sector is dominating the biologics outsourcing market. Owing to the increasing use of different kits & reagents in numerous clinical trials and other microbiological activities. 

Considering the applications of global biologics market, vaccine & therapeutics development segment is anticipated to hold the largest market share. The factors such as increasing awareness about disease prevention by vaccination and rising investments in R&D of vaccine segment will boost the segment in near future

North America is the largest market for pharmaceutical/biopharmaceutical research, conducting more than three-quarters of the world’s research and development and holding the IP rights for most of the world’s new drug products, hence it the dominating the biologics outsourcing market globally. The Asia Pacific is anticipated to be the most lucrative region in the global biologics outsourcing market. Owing to the increasing pharmaceutical sector in the region and rising government initiatives for the healthcare industry. 

Industry Players

The report includes detailed profiles of the prominent market players that are trending in the market. The list of the players that are compiled in the report is Boehringer Ingelheim GmbH, Catalent, Inc., GenScript, Innovent Biologics, Inc., Syngene, Shanghai Medicilon inc., GL Biochem Corporation Ltd., GVK Biosciences Private Limited, Horizon Discovery Group plc. Innovent Biologics, Inc., Selexis SA, Lonza, Abzena Plc, Adimab LLC., and much more.

The prominent market players maintain the competitive edge in the global market by making investments in the mergers and acquisitions and by increasing their product portfolio. In October 2017, Boehringer Ingelheim and Siamab Therapeutics, Inc. announced that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor-associated carbohydrate antigens (TACAs). 

 


Related Reports

Migraine Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-2605 | Report Format:

Global Migraine Drugs Market: Overview About 1214% of people around the world suffer from a Migraine; it is a type of a headache. According to regional and international rules, migraine is classified by the nature of the attack and its frequency into a chronic migraine and episodic migraine. Pro...Read More

Cardiovascular Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-2602 | Report Format:

Global Cardiovascular Drugs Market: Overview Cardiovascular diseases are popularly known as heart diseases. These diseases are associated with circulatory system and heart. To list a few common cardiovascular diseasesrheumatic heart disease, hypertensive heart disease, inflammatory heart disease...Read More

Sports Medicine Market by Product Type (Body Reconstruction Products, Body Support & Recovery and Accessories) and by Application like Shoulder Injuries, Ankle & Foot Injuries, Elbow & Wrist Injuries, Back & Spine Injuries, Hip & Groin Injuries, Knee Injuries and Other Injuries - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2022

Feb-2018 | Price : $ 4199.00 | Pages: 110 | Report Code: ZMR-2598 | Report Format:

The report covers forecast and analysis for the Sports Medicine market on a global and regional level. The study provides historical data from 2014 along with a forecast from 2018 to 2022 based on revenue (USD Million). The study includes drivers and restraints for the Sports Medicine market along...Read More

Cancer Immunotherapy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-2587 | Report Format:

Global Cancer Immunotherapy Market: Overview Due to the attendance of a pool of large and small companies, the global cancer immunotherapy market makes for an uneven competitive market. Healthcare suppliers are aiming at enhancing treatments and lowering in the reappearance of cancer after chemo...Read More

Europe Precision Medicine Market byTechnology (Big Data Analytics, Bioinformatics, Gene sequencing, Drug Discovery, Companion Diagnostic, and Others); End-users (Diagnostic tool companies, Healthcare IT/ Big data companies, Pharma & Biotech companies, and Clinical Labs); and for Application (Oncology, CNS,Immunology, Respiratory and Others) – Europe Industry Analysis, Size, Share, Growth, Trends, and forecast 2014 – 2022

Feb-2018 | Price : $ 4199.00 | Pages: 120 | Report Code: ZMR-2578 | Report Format:

Report Brief The report covers forecast and analysis for the precision medicines market on regional and country level The report includes the positive and the negative factors that are influencing the growth of the market Detailed information about the market opportunities are discussed The k...Read More

Why Choose Us ?

24/5 Research support

Resolved your research queries from industry expert. Request for a free research sample before report purchase.

Custom research service

Ask the Analyst to customize an exclusive study to serve your research needs.

Quality & Accuracy

Zion Market Research reports offers best quality reports based on various authentic and accurate data findings.

Customer Satisfaction

We ensure that our client's all research needs are met with customized, in-depth analysis solutions.

Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.

Quick Inquiry